The Effectiveness of Titanium-Prepared Platelet-Rich Fibrin on Angiogenic Biomarkers in Gingival Crevicular Fluid

The Effect of Titanium-Prepared Platelet-Rich Fibrin (T-PRF) Treatment on the Angiogenic Biomarkers in Gingival Crevicular Fluid (GCF) in Infrabony Defects of Patients With Chronic Periodontitis: A Randomized Controlled Clinical Trial

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02692079

Acronym

T-PRF

Enrollment

Registered

2016-02-25

Start date

2014-02-28

Completion date

2014-11-30

Last updated

2016-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Periodontitis, Intrabony Periodontal Defect

Keywords

Angiogenesis, Bilateral infrabony defect, Flap surgery, Titanium-prepared, platelet-rich ﬁbrin

Brief summary

This study investigates the effect of titanium-prepared platelet-rich fibrin (T-PRF) treatment on the angiogenic biomarkers in gingival crevicular fluid (GCF) in infrabony defects of patients with chronic periodontitis. In each patient, the infrabony defect of one side of arch was designated as control group (allograft), while the infrabony defect on the contralateral side of same arch was designated as test group (allograft+T-PRF).

Detailed description

Platelets are the cells initiating the wound healing and also supporting it by secreting various growth factors actively. These growth factors released by platelets act the increase of connective tissue healing, bone regeneration and repair, fibroblast mitogenesis, wound angiogenesis and the activation of macrophages by stimulating cell proliferation signals. Titanium-prepared, platelet-rich fibrin (T-PRF), is a new platelet concentrate, is formed in titanium tubes may be more efficient to activate platelets in comparison with glass tubes.The titanium tubes is utilized to refrain any inverse effects of glass tubes and also silica.

Interventions

PROCEDURET-PRF

Flap Surgery

PROCEDUREAllograft

Flap Surgery

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

26 Years to 59 Years

Healthy volunteers

Inclusion criteria

* Clinical Diagnosis of Chronic Periodontitis * The presence of two or three-wall intrabony defects≥3 mm deep along with an interproximal probing depth ≥5 mm after non-surgical periodontal therapy

Exclusion criteria

* Systemic illnesses * Any medications known to affect the outcomes of periodontal surgery * Pregnancy and lactation

Design outcomes

Primary

Measure	Time frame
Platelet-derived growth factor-BB (ng/µl) , vascular endothelial growth factor-A (ng/µl), fibroblast growth factor-2 (ng/µl), anjiogenin (ng/µl), angiostatin (ng/µl)	Within the first 30 days after surgery

Secondary

Measure	Time frame
The Volume of Gingival Crevicular Fluid (microliter)	Within the first 30 days after surgery

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026